Drug Trial Radar · NCT02623556
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
Last checked: Nov 19, 2026Latest source record: Apr 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,090
Planned (sponsor's estimate)
Start
Dec 2015
Primary completion
Mar 2018
Study completion Mar 2018
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Public Health Clinical Center; Tianjin Haihe Hospital; Air Force Military Medical University, China; Proswell Medical Corporation; Wuhan Institute for Tuberculosis Control; Beijing Chest Hospital; Wuxi Hospital for Infectious Diseases; First Affiliated Hospital of Chongqing Medical University; Fuzhou Pulmonary Hospital of Fujian; Zhenjiang Third People's Hospital; Anhui Provincial Hospital; Shenzhen Third People's Hospital
- First posted
- Dec 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
720 cases TB (Tuberculosis patients) participants、360 cases non-TB participants with lung disease and suspected TB patients who all meet the standard are divided into different groups through a randomized and blind method. Every subject inject intradermally ESAT6-CFP10 and TB-PPD (tuberculin purified protein derivative) in different arms of the same person by blind method. Specific gama-interferon (γ-IFN) detection is needed before the injection.Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe all kind of adverse events.
Conditions
- Tuberculosis
Interventions
ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right armBiological
All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left armBiological
All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patientsTime frame: within 72h after injection
- Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in TB patientsTime frame: within 72h after injection
- Immune response of left arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung diseaseTime frame: within 72h after injection
- Immune response of right arm (random injected ESAT6-CFP10 or PPD) from the size of induration or redness in non-TB subjects with lung diseaseTime frame: within 72h after injection
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Wuxi NO.5 People's Hospital
Wuxi, Jiangsu, China
Shanghai Public Health clinical Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.